¾ÅÖÝkuÓιÙÍø

¡°ÊØÎÀÉö¹¦Ð§¡ªIgAÉöÓѰٳǹ«ÒæÐС±³¤É³Õ¾ÔÚ¾ÅÖÝkuÓιÙÍø´óÒ©·¿ÎåÒ»ÆðµêÀֳɾÙÐÐ

¾ÅÖÝ¿áÓÎ(¿áÓΡ¤kuÓÎ)¹Ù·½ÍøÕ¾
IgAÉö²¡ÊÇÈ«Çò¹æÄ£ÄÚ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡Ö®Ò»£¬£¬£¬£¬£¬ÔÚÎÒ¹ú¼°¶«Ñǹú¼ÒÓÈΪ³£¼û¡£¡£¡£¡£¡£¡£¡£¡£´ó´ó¶¼»¼ÕßÌåÏÖΪÉöÔಡ»ºÂýÏ£Íû£¬£¬£¬£¬£¬Êǵ¼ÖÂÇàÄêÈËÖÕδÆÚÉö²¡µÄ×î³£¼û²¡Òò£¬£¬£¬£¬£¬¸ø¼ÒÍ¥ºÍÉç»á´øÀ´Á˼«Öصļ²²¡¼ç¸º¡¾1¡¿¡£¡£¡£¡£¡£¡£¡£¡£ÔÚIgAÉö²¡µÄÖÎÁÆÀú³ÌÖУ¬£¬£¬£¬£¬»¼Õß½ÌÓýÊÇÖ÷Òª»·½Ú£¬£¬£¬£¬£¬¶øÏÖÔÚIgAÉö²¡»¼Õߵļ²²¡ÈÏÖª¡¢×ÔÎÒ¹ÜÀíÄÜÁ¦ÈÔÓнϴóÌáÉý¿Õ¼äºÍδ֪×ãÐèÇ󡣡£¡£¡£¡£¡£¡£¡£
ΪÁË×ÊÖú¸ü¶àIgAÉö²¡»¼Õß»ñÈ¡ÕïÁÆÖªÊ¶¡¢Ìá¸ß¼²²¡¹ÜÀíÄÜÁ¦£¬£¬£¬£¬£¬¡°ÊØÎÀÉö¹¦Ð§¡ªIgAÉöÓѰٳǹ«ÒæÐС±ÏîÄ¿³¤É³Õ¾Ô˶¯ÔÚ¾ÅÖÝkuÓιÙÍø´óÒ©·¿ÎåÒ»Æðµê¾ÙÐУ¬£¬£¬£¬£¬Í¨¹ýÏßÉÏÏßÏÂÏàÍŽáµÄÉöÓѽÌÓýÔ˶¯¡¢Ò½»¼»¥¶¯¼°¿ÆÆÕÈö²¥£¬£¬£¬£¬£¬Íƶ¯»¼ÕßÔçÕïÔçÖΣ¬£¬£¬£¬£¬´Ó¶øÑÓ»º¼²²¡Ï£Íû£¬£¬£¬£¬£¬Ìá¸ßÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£¡£¡£¡£
¾ÅÖÝ¿áÓÎ(¿áÓΡ¤kuÓÎ)¹Ù·½ÍøÕ¾
³¤É³ÊÐÉö´È¹«Òæ·þÎñÖÐÐÄÀíʳ¤ºî¼ÑÏÖ³¡Ö´ǣ¬£¬£¬£¬£¬·ÖÏí¹«ÒæÁ¦Á¿ÔÚÉö²¡Ôçɸ¡¢»¼Õß½ÌÓý¼°ÐÄÀíÖ§³ÖµÈ·½ÃæµÄʵ¼ùÂÄÀú¡£¡£¡£¡£¡£¡£¡£¡£
±¾´ÎÔ˶¯Ô¼ÇëÁËÖÐÄÏ´óÑ§ÏæÑÅÈýÒ½ÔºÉöÄÚ¿ÆÁõ¼Íʵ½ÌÊÚ´øÀ´Ö÷Ìâ½²×ù£¬£¬£¬£¬£¬ÒÔÕæÊµ°¸Àý½â˵IgAÉö²¡µÄ·¢²¡ÌåÏÖ¡¢ÉúÑÄÒûʳԭÔò¡¢IgAÉö²¡Ò©ÎïÕïÁƼƻ®µÈ֪ʶ£¬£¬£¬£¬£¬ÃãÀø¸÷ÈË׼ȷÊìϤ¼²²¡£¡£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬×öµ½ÔçÕï¡¢ÔçÖΡ¢Ô綨ÐÄ¡£¡£¡£¡£¡£¡£¡£¡£
¾ÅÖÝ¿áÓÎ(¿áÓΡ¤kuÓÎ)¹Ù·½ÍøÕ¾
ÔÚÏÖ³¡´ðÒÉ»·½Ú£¬£¬£¬£¬£¬Áõ¼Íʵ½ÌÊÚÕë¶Ô»¼ÕßÌåÌùµÄÎÊÌâÖðÒ»½â´ð¡£¡£¡£¡£¡£¡£¡£¡£¹ØÓÚÐí¶àÉöÓÑÌåÌùµÄ²¼µØÄ峦ÈܽºÄÒµÄÎÊÌ⣬£¬£¬£¬£¬Áõ½ÌÊÚ½â´ð£º²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÊÇÈ«ÇòÊ׸ö°ÐÏòIgAÉö²¡Ô´Í·–³¦µÀð¤Ä¤ÃâÒߵĶÔÒòÖÎÁÆÐÂÒ©£¬£¬£¬£¬£¬ÊÇÊ׸öͬʱ±»ÃÀ¹úFDA¡¢Å·ÖÞEMA¡¢ÖйúNMPAÈý´óȨÍþÒ©¼à»ú¹¹Åú×¼ÓÃÓÚÖÎÁÆIgAÉö²¡µÄÁ¢ÒìÒ©Î2-7¡¿£¬£¬£¬£¬£¬¾ßÓÐÖØ´óÁÙ´²ÒâÒå¡£¡£¡£¡£¡£¡£¡£¡£ËüÊÊÓÃÓÚ¾ßÓÐÏ£ÍûΣº¦µÄÔ­·¢ÐÔIgAÉö²¡³ÉÄ껼Õߣ¬£¬£¬£¬£¬¿ÉÒÔïÔÌ­Éö¹¦Ð§Ëðʧ£¬£¬£¬£¬£¬Í¬Ê±½µµÍÂѰ×Äò¡¢¸ÄÉÆÑªÄò¡£¡£¡£¡£¡£¡£¡£¡£
²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÔÚ¾ÅÖÝkuÓιÙÍø´óÒ©·¿ÓÐÊÛ£¬£¬£¬£¬£¬ÎÒÃÇÆð¾¢ÅäºÏÁÙ´²ÐèÇ󣬣¬£¬£¬£¬ÊµÊ±ÎÈÍ׵ؽ«Ò©Æ·ÅäË͵½»¼ÕßÐèÒªµÄµØ·½¡£¡£¡£¡£¡£¡£¡£¡£
¾ÅÖÝkuÓιÙÍø²¿·ÖDTPÒ©·¿ÐÅÏ¢Ò»ÀÀ£º
¾ÅÖÝ¿áÓÎ(¿áÓΡ¤kuÓÎ)¹Ù·½ÍøÕ¾
²Î¿¼ÎÄÏ×£º

1.ÐÂÒ©Ó¦ÓúÍÖÎÁÆÕ½ÂÔת±äÓÐÍû¸ÄÉÆIgAÉö²¡»¼ÕßµÄÔ¤ºó[J]. ÖлªÒ½Ñ§ÐÅÏ¢µ¼±¨,2024,39(16):11. DOI:10.3760/cma.j.issn.1000-8039.2024.16.118.
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
ÉÏһƪÎÄÕÂ
¾ÅÖÝkuÓιÙÍøÖØ°õÐÂÆ·ÁÁÏà¹ãÖÝÒ©½»»á£¬£¬£¬£¬£¬ÏÖ³¡Ç©Ô¼¿ªÍغ£ÄÚÍâÊг¡
ÏÂһƪÎÄÕÂ
¿ÆÑ§°ÍÊ¿¿ª½ø¾ÅÖÝkuÓιÙÍø£¬£¬£¬£¬£¬´ò¿¨ÖÐÒ½Ò©¿Æ¼¼ÎÄ»¯ºþÄÏÊ¡¿ÆÆÕ»ùµØ
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿